{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:50:23Z","timestamp":1785790223889,"version":"3.56.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>\n                      To prospectively evaluate the diagnostic performance of\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTA-Bombesin PET\/CT compared with\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT in breast cancer (BC), emphasizing its utility across molecular subtypes and nodal staging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      Twenty-four patients with biopsy-proven BC who underwent both\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTA-Bombesin and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT were included. Imaging findings were analyzed on a per-lesion and per-patient basis for primary tumor detection, axillary lymph-node involvement, and distant metastases. Quantitative parameters (SUVmax, MTV, and tumor-to-background ratios) were compared across histopathologic and receptor subgroups, with histopathology as the reference standard.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTA-Bombesin visualized 92.3% of primary tumors, achieving comparable sensitivity to\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG (84.6%) but higher specificity in nodal staging (100% vs. 53.8%). Bombesin uptake correlated strongly with estrogen receptor positivity and a lower Ki-67 index (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05). In a limited number of patients with distant metastases (n=4), FDG appeared to detect hepatic and pulmonary lesions, whereas Bombesin identified additional osseous and peritoneal lesions. Physiological uptake was lower in the liver and bone marrow but higher in the blood pool for Bombesin. Emerging antagonist data indicate further improvements in tumor-to-background ratios and potential theranostic applications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTA-Bombesin PET\/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG, particularly in hormone-receptor\u2013positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006582","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:00:20Z","timestamp":1781686820000},"page":"e759-e767","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Value of 68Ga-DOTA-Bombesin PET\/CT Compared With 18F-FDG PET\/CT in the Staging of Breast Cancer"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-8757","authenticated-orcid":false,"given":"Mehmet Can","family":"Baloglu","sequence":"first","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-4538","authenticated-orcid":false,"given":"Rahime","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8509-1583","authenticated-orcid":false,"given":"Zehranur","family":"Tosunoglu","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0967-0339","authenticated-orcid":false,"given":"Ahmet Ertugrul","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-4261","authenticated-orcid":false,"given":"\u00d6mer Faruk","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-4830","authenticated-orcid":false,"given":"Ediz","family":"Beyhan","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-9964","authenticated-orcid":false,"given":"\u00d6zge","family":"Erol Fenercioglu","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2268-9606","authenticated-orcid":false,"given":"G\u00f6ksel","family":"Alcin","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"Ergul","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7622-7277","authenticated-orcid":false,"given":"Tevfik Fikret","family":"Cermik","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ac\u0131badem Maslak Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-7639","authenticated-orcid":false,"given":"\u00c7i\u011fdem","family":"Usul Afsar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Istanbul Training and Research Hospital, \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-8883","authenticated-orcid":false,"given":"Esra","family":"Arslan","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine, University of Health Sciences, Istanbul Training and Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"R1-20260803","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacr.2020.05.002","article-title":"Current guidelines and gaps in breast cancer screening","volume":"17","author":"Monticciolo","year":"2020","journal-title":"J Am Coll Radiol"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/diagnostics13040597","article-title":"The role of PET\/CT in breast cancer","volume":"13","author":"Hadebe","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R4-20260803","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40336-021-00426-z","article-title":"Breast cancer: initial workup and staging with FDG PET\/CT","volume":"9","author":"Groheux","year":"2021","journal-title":"Clin Transl Imaging"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1634\/theoncologist.2011-0089","article-title":"FDG-PET\/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer","volume":"16","author":"Niikura","year":"2011","journal-title":"Oncologist"},{"key":"R6-20260803","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1159\/000507707","article-title":"How useful are tumor markers in detecting metastases with FDG-PET\/CT during breast cancer surveillance?","volume":"98","author":"Corso","year":"2020","journal-title":"Oncology"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","article-title":"Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA)","volume":"51","author":"Vaz","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2967\/jnumed.115.161455","article-title":"Comparison of 18F-FDG PET\/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma","volume":"56","author":"Hogan","year":"2015","journal-title":"J Nucl Med"},{"key":"R9-20260803","doi-asserted-by":"crossref","first-page":"W304","DOI":"10.2214\/AJR.11.7130","article-title":"False-positive lesions mimicking breast cancer on FDG PET and PET\/CT","volume":"198","author":"Adejolu","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"100006","DOI":"10.1016\/j.eanmj.2025.100006","article-title":"18F] FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 3.0","volume":"1","author":"Boellaard","year":"2025","journal-title":"The EANM Journal"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00259-016-3563-6","article-title":"(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients","volume":"44","author":"Sathekge","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20260803","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41824-023-00176-3","article-title":"Head-to-head comparison of (18)F-FDG and (18)F-FES PET\/CT for initial staging of ER-positive breast cancer patients","volume":"7","author":"Kiatkittikul","year":"2023","journal-title":"Eur J Hybrid Imaging"},{"key":"R14-20260803","doi-asserted-by":"crossref","first-page":"e2423435","DOI":"10.1001\/jamanetworkopen.2024.23435","article-title":"ER-targeted PET for initial staging and suspected recurrence in ER-positive breast cancer","volume":"7","author":"Ulaner","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R15-20260803","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","article-title":"Expression of Gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors","volume":"58","author":"Morgat","year":"2017","journal-title":"J Nucl Med"},{"key":"R16-20260803","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2967\/jnumed.119.234971","article-title":"Imaging the distribution of Gastrin-releasing peptide receptors in cancer","volume":"61","author":"Baratto","year":"2020","journal-title":"J Nucl Med"},{"key":"R17-20260803","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.7150\/thno.14958","article-title":"Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist (68)Ga-RM2 And PET","volume":"6","author":"Stoykow","year":"2016","journal-title":"Theranostics"},{"key":"R18-20260803","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/RLU.0000000000002209","article-title":"68Ga-NOTA-RM26 PET\/CT in the evaluation of breast cancer: a pilot prospective study","volume":"43","author":"Zang","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R19-20260803","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7150\/thno.22601","article-title":"68)Ga-BBN-RGD PET\/CT for GRPR and Integrin alpha(v)beta(3) imaging in patients with breast cancer","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"key":"R20-20260803","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20260803","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00259-015-3232-1","article-title":"Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [(6)(8)Ga]SB3 and PET\/CT","volume":"43","author":"Maina","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-20260803","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/ph15070772","article-title":"(64)Cu-SAR-Bombesin PET-CT imaging in the staging of estrogen\/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a phase I trial","volume":"15","author":"Wong","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R23-20260803","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cpet.2024.03.004","article-title":"Gastrin releasing peptide receptors-targeted PET diagnostics and radionuclide therapy for prostate cancer management: preclinical and clinical developments of the past 5 years","volume":"19","author":"Dalm","year":"2024","journal-title":"PET Clin"},{"key":"R24-20260803","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40644-024-00658-y","article-title":"Advances of radiolabeled GRPR ligands for PET\/CT imaging of cancers","volume":"24","author":"Ma","year":"2024","journal-title":"Cancer Imaging"},{"key":"R25-20260803","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2967\/jnumed.114.153023","article-title":"In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer","volume":"56","author":"Dalm","year":"2015","journal-title":"J Nucl Med"},{"key":"R26-20260803","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/pharmaceutics17081000","article-title":"The impact of the injected mass of the Gastrin-releasing peptide receptor antagonist on uptake in breast cancer: lessons from a phase I trial of [(99m)Tc]Tc-DB8","volume":"17","author":"Bragina","year":"2025","journal-title":"Pharmaceutics"},{"key":"R27-20260803","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"R28-20260803","doi-asserted-by":"crossref","first-page":"e0170536","DOI":"10.1371\/journal.pone.0170536","article-title":"Prospects of targeting the Gastrin Releasing peptide receptor and somatostatin receptor 2 for nuclear imaging and therapy in metastatic breast cancer","volume":"12","author":"Dalm","year":"2017","journal-title":"PLoS One"},{"key":"R29-20260803","doi-asserted-by":"crossref","first-page":"2320301","DOI":"10.1080\/07853890.2024.2320301","article-title":"Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann Med"},{"key":"R30-20260803","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13550-025-01204-y","article-title":"First-in-human experience with GRPR antagonist [(68)Ga]Ga-NOTA-PEG(2)-RM26 in prostate and breast cancer patients using PET\/CT","volume":"15","author":"Bjareback","year":"2025","journal-title":"EJNMMI Res"},{"key":"R31-20260803","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2967\/jnumed.124.268896","article-title":"Diagnostic potential of (68)Ga-NeoB PET\/CT with estrogen receptor- and progesterone receptor-positive breast cancer undergoing staging or restaging for metastatic disease","volume":"66","author":"Sabahi","year":"2025","journal-title":"J Nucl Med"},{"key":"R32-20260803","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.124.269132","article-title":"First-in-human serum stability studies of [(177)Lu]Lu-AMTG: a step toward improved GRPR-targeted radiopharmaceutical therapy","volume":"66","author":"Felber","year":"2025","journal-title":"J Nucl Med"},{"key":"R33-20260803","doi-asserted-by":"crossref","first-page":"108961","DOI":"10.1016\/j.nucmedbio.2024.108961","article-title":"Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: a preclinical study of the theranostic pair [(55)Co]Co- and [(177)Lu]Lu-DOTA-RM26","volume":"138-139","author":"Baun","year":"2024","journal-title":"Nucl Med Biol"},{"key":"R34-20260803","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/tomography11080083","article-title":"Emerging PET imaging agents and targeted radioligand therapy: a review of clinical applications and trials","volume":"11","author":"Palihati","year":"2025","journal-title":"Tomography"},{"key":"R35-20260803","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s41181-025-00374-3","article-title":"RM2 and DB15 analogues bearing [(177)Lu]Lu-DOTAGA via different linkers, as radiotherapeutics: a head-to-head comparative study","volume":"10","author":"Kanellopoulos","year":"2025","journal-title":"EJNMMI Radiopharm Chem"},{"key":"R36-20260803","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2967\/jnumed.124.269444","article-title":"A vision for gastrin-releasing peptide receptor targeting for imaging and therapy: perspective from academia and industry","volume":"66","author":"Morgat","year":"2025","journal-title":"J Nucl Med"},{"key":"R37-20260803","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1093\/annonc\/mdt390","article-title":"Discordance in ERalpha, PR and HER2 receptor status across different distant breast cancer metastases within the same patient","volume":"24","author":"Hoefnagel","year":"2013","journal-title":"Ann Oncol"},{"key":"R38-20260803","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/ph18040449","article-title":"Novel (177)Lu-labeled [Thz(14)] Bombesin (6-14) derivatives with low pancreas accumulation for targeting gastrin-releasing peptide receptor-expressing cancer","volume":"18","author":"Wang","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"R39-20260803","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/ph18020234","article-title":"Synthesis and evaluation of (68)Ga- and (177)Lu-labeled [diF-Pro(14)]Bombesin(6-14) analogs for detection and radioligand therapy of gastrin-releasing peptide receptor-expressing cancer","volume":"18","author":"Wang","year":"2025","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:01:58Z","timestamp":1785787318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006582","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"2026-01-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}